Literature DB >> 6327542

Immunoregulation by macrophages. III. Prostaglandin E suppresses lymphocyte activation but not macrophage effector function during Salmonella enteritidis infection.

J Cahill, K E Hopper.   

Abstract

Peritoneal macrophages obtained during primary or secondary infection with Salmonella enteritidis differ in the proportions of subpopulations with the capacity to secrete prostaglandin E (PGE) and interleukin 1 (IL1) and have bactericidal and tumoricidal activities in vitro. Using indomethacin in vivo and PGE in vitro we have studied the regulation of subpopulations of lymphocytes and macrophages by PGE during the inflammatory reaction. Indomethacin treatment promoted clearance of the Salmonella and a 50-90% increase in macrophages recovered from the peritoneal cavity in both primary and secondary infected animals. Whilst blocking the capacity of macrophages to secrete PGE in vitro the indomethacin treatment did not alter their bactericidal (or tumoricidal) activity nor their cyclic AMP response to PGE2. A major effect of indomethacin in vivo and of PGE2 in vitro however, was on the production and expression of IL1 and IL2. Secretion of IL1 by macrophages in vitro was greatly enhanced in indomethacin treated mice and was suppressed in vitro by PGE2. Prostaglandin E2 also inhibited IL1 dependent T-lymphocyte differentiation. IL2 secretion and IL2 dependent blast cell proliferation in vitro and sensitivity of the cells to PGE2 inhibition increased through this sequence of reactions. Lymphocyte populations harvested at intervals during primary or secondary infection differed in their cyclic AMP response to PGE2 and in IL2 secretion in vitro. This may be related to changes in the proportions of lymphocyte subsets having Lyt 1+ markers. We conclude that peritoneal macrophages from Salmonella infected mice differ in their capacity to secrete PGE and IL1.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6327542     DOI: 10.1016/0192-0561(84)90029-8

Source DB:  PubMed          Journal:  Int J Immunopharmacol        ISSN: 0192-0561


  6 in total

1.  Potential antiinflammatory effects of interleukin 4: suppression of human monocyte tumor necrosis factor alpha, interleukin 1, and prostaglandin E2.

Authors:  P H Hart; G F Vitti; D R Burgess; G A Whitty; D S Piccoli; J A Hamilton
Journal:  Proc Natl Acad Sci U S A       Date:  1989-05       Impact factor: 11.205

2.  Placentally derived prostaglandin E2 acts via the EP4 receptor to inhibit IL-2-dependent proliferation of CTLL-2 T cells.

Authors:  N Kvirkvelia; I Vojnovic; T D Warner; V Athie-Morales; P Free; N Rayment; B M Chain; T W Rademacher; T Lund; I M Roitt; P J Delves
Journal:  Clin Exp Immunol       Date:  2002-02       Impact factor: 4.330

3.  The role of prostaglandin E2 in immune suppression following injury.

Authors:  J T Grbic; J A Mannick; D B Gough; M L Rodrick
Journal:  Ann Surg       Date:  1991-09       Impact factor: 12.969

Review 4.  Prostaglandin E2 and T cells: friends or foes?

Authors:  Vinatha Sreeramkumar; Manuel Fresno; Natalia Cuesta
Journal:  Immunol Cell Biol       Date:  2011-09-27       Impact factor: 5.126

5.  Evidence for a role for interleukin-17, Th17 cells and iron homeostasis in protective immunity against tuberculosis in cynomolgus macaques.

Authors:  Alice S Wareham; Julia A Tree; Philip D Marsh; Philip D Butcher; Mike Dennis; Sally A Sharpe
Journal:  PLoS One       Date:  2014-02-04       Impact factor: 3.240

6.  Amelioration of B16F10 melanoma lung metastasis in mice by a combination therapy with indomethacin and interleukin 2.

Authors:  R S Parhar; P K Lala
Journal:  J Exp Med       Date:  1987-01-01       Impact factor: 14.307

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.